SCHEMBL3968488

SCHEMBL3968488

COc1cc2cc(C)c(Cl)nc2cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PGK1 P00558 3/20 0.51
PDGFRB P09619 8/20 0.44
PDGFRA P16234 8/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
NQO2 P16083 1/20 0.42
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12970118 0.86 ALDH1A1 (0.40) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL22549140 0.86 PGK1 (0.42) ALDH1A1KDM4ESMN1; SMN2PGK1CYP1A2
SCHEMBL12970124 0.86 PGK1 (0.42) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL29732651 0.86 PGK1 (0.42) ALDH1A1KDM4ESMN1; SMN2PGK1CYP1A2
SCHEMBL9755384 0.80 PDGFRB (0.50) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL1291729 0.79 PGK1 (0.68) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL31530749 0.79 PGK1 (0.68) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL28141256 0.77 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL9755422 0.77 NQO2 (0.60) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB
SCHEMBL13335967 0.77 KDM4E (0.49) ALDH1A1KDM4ESMN1; SMN2PGK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012133607-A1 PYRAZOLE COMPOUND アステラス製薬株式会社 (JP) 2012-10-04 WO disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
WO-2008025509-A1 BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-06 WO disclosed
EP-1474401-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2004-11-10 EP disclosed
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC 2003-12-25 US disclosed
WO-2003066604-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HRH3, HRH2, HRH4 ALDH1A1 2719/4885KDM4E 1574/4885SMN1; SMN2 4208/4885
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HRH3, HRH2, HRH4 ALDH1A1 2719/4885KDM4E 1574/4885SMN1; SMN2 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.